紅日藥業(300026.SZ)業績快報:2020年度淨利潤升42.99%至5.76億元
格隆匯 2 月 25日丨紅日藥業(300026.SZ)發佈2020年度業績快報,實現營業總收入64.88億元,同比增長29.68%;營業利潤6.56億元,同比增長35.68%;利潤總額6.85億元,同比增長41.40%;歸屬於上市公司股東的淨利潤5.76億元,同比增長42.99%;基本每股收益0.19元。
2020年度,公司以戰略為指引,以經營計劃為導向,整體上下同心,充分發揮自身優勢,積極投入到國內疫情防控工作中,利用國內快速復工復產的機會,拓展國外銷售渠道,加大醫療器械產品的出口業務,在逆境中求發展。醫療器械產品國外訂單量較上年同期大幅度增長;醫療器械配送業務積極開拓新的商業模式,業務規模迅速擴張;成品藥血必淨注射液銷售數量較上年同期穩步增長,新產品鹽酸莫西沙星氯化鈉注射液上市銷售並列入國家藥品集中採購品種;中藥配方顆粒和原輔料業務平穩發展,收入較上年同期略有增長。
2020年度,公司營業總收入較上年同期增長29.68%,主要原因是本年度醫療器械國外銷售及醫療器械配送業務增長所致;營業利潤、利潤總額、歸屬於上市公司股東的淨利潤、基本每股收益分別較上年同期增長35.68%、41.40%、42.99%和35.71%,主要原因是本年收入增長對利潤的影響及本年計提商譽減值減少所致。
公司根據《企業會計準則第8號-資產減值》的相關規定,以2020年12月31日為基準日對全資子公司北京超思電子技術有限責任公司和湖州展望藥業有限公司進行商譽減值測試。根據公司財務部門初步測試結果,本年未發生減值。商譽最終數據有待評估機構、會計師事務所確定。敬請廣大投資者謹慎決策,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.